Exosome Assays for Osteoarthritis Stem Cell Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack consistency in selecting patients who will respond positively to stem cell therapy for osteoarthritis, as the heterogeneity of patient responses and inflammatory host functions can neutralize or induce stem cells to form scar tissue, leading to variable therapeutic outcomes.
Innovation Solution
The use of exosomes as biological markers to assess the likelihood of success in stem cell therapy by identifying specific molecular profiles associated with resistance or efficacy, including markers such as CD133, CD34, CD90, and miRNA expression, to determine patient suitability before stem cell administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell therapy is administered to treat osteoarthritis, then regenerative healing and antiinflammatory activities are achieved, but heterogeneous patient responses occur due to inflammatory host functions that can neutralize stem cells or induce scar tissue formation
Solution Approach 1:
The patent applies preliminary action by performing exosome-based screening assays before stem cell therapy administration to identify patients who are most likely to respond positively. The method measures exosome concentrations and molecular profiles (such as CD133, CD34, CD90, and miRNA expression) in advance, allowing clinicians to select appropriate candidates before treatment begins, thereby improving outcome consistency and reducing adverse responses.
2Measurement precision
If biological markers are used to screen patients for stem cell therapy, then patient selection is improved, but current methods lack consistent predictive accuracy for therapy response
Solution Approach 1:
The patent applies parameter changes by utilizing exosomes as a novel biological marker system with specific molecular parameters (exosome concentrations, CD133, CD34, CD90 surface markers, and miRNA expression profiles). These parameters provide more precise and consistent predictive information about patient response to stem cell therapy compared to previous screening methods, thereby improving both measurement precision and predictive reliability.
Data Source
AI summary
Disclosed are means and methods useful in selecting osteoarthritis patients most likely to respond to regenerative medicine therapy. One means of practicing the invention is to determine quantity and quality of inflammatory exosomes generated from the tissue adjacent to the injured cartilage. In another embodiment the invention provides detection of exosomes produced by inflammatory processes local or systemic to the body. In some embodiments therapies are tailored to the extent of inflammatory exosomes.